Key facts
- It has raised $10K; the latest was Later Stage VC in Dec 2024.
- Notable investors include Venture Kick, Kickfund, Fondation Eclosion, Fongit, Matwin.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Abologix
- ·The full record, as it builds
Funding rounds
No funding rounds for Abologix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abologix
Operator of a biopharmaceutical company intended to develop novel therapeutics designed for oncology treatment. The company offers a monoclonal antibody treatment by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein, enabling healthcare providers to treat patients with several oncological medical indications.
- Sector
- Healthcare
- HQ
- Geneva, Switzerland
- Founded
- 2018
- Website
- abologix.com/
- Ownership
- Privately Held (backing)
Abologix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abologix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abologix in its N-PORT filings yet. We sweep new filings monthly.